Partner in Progress: Ferring Pharmaceuticals

BCAN is proud to partner with Ferring Pharmaceuticals in our shared quest to create better todays and more tomorrows for bladder cancer patients and families.

Ferring’s ADSTILADRIN® (nadofaragene firadenovec-vncg) was approved in the United States in 2022 and is fully available for appropriate patients as a treatment that may help people live better lives on their bladder cancer journey.

Click here to learn more about ADSTILADRIN.

A Bladder Cancer Patient: Mike’s Story

Webinar: Expanding Treatment Options for Non-muscle Invasive Bladder Cancer: Introducing a novel therapy for those who do not respond to BCG

Watch a webinar with urologist researcher Colin P. Dinney MD, Chairman of the Department of Urology at the University of Texas MD Anderson Cancer Center, as he explains this new treatment option that uses the patient’s own bladder wall cells to enhance the body’s natural defenses to fight cancer.

Podcast: An Option for Bladder Cancer Patients When BCG Fails Them

Listen to a fascinating podcast with Bladder Cancer Matters host Rick Bangs who kicks off BCAN’s 20th anniversary “Partners in Progress” series with Karishma Parikh of Ferring Pharmaceuticals.

Ferring Access Support—Patient Assistance Program (PAP)

Ferring’s Patient Assistance Program offers patient assistance, coverage support, and other valuable resources for eligible uninsured/underinsured patients, including:

• Referrals to third-party organizations including 501(c)(3) charities, patient support and education groups, and state health exchange resources
• Help with scheduling appointments and staying on top of treatment

Clinical Trials

Listed below are bladder cancer clinical trials sponsored by Ferring. Click to read more about the trials, including summaries, eligibility and trial locations.

• Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
• Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

About Adstiladrin:

INDICATION

ADSTILADRIN is a treatment for adults who have all the following:

• High-risk non–muscle-invasive bladder cancer (NMIBC)
• Cancer that is not responding to Bacillus Calmette-Guérin (BCG) therapy
• Carcinoma in situ (CIS) with or without other high-grade tumors

IMPORTANT SAFETY INFORMATION

Who should not receive ADSTILADRIN?

Do not receive ADSTILADRIN if you have a sensitivity to interferon alfa or any of its components.

What is the most important information I should know about ADSTILADRIN?

Individuals who are immunosuppressed or immune-deficient should not prepare, administer, receive or come into contact with ADSTILADRIN.

What should I tell my healthcare provider?

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of ADSTILADRIN?

The most common side effects of ADSTILADRIN include:
Urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in your urine.

These are not all the possible side effects of ADSTILADRIN. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING.

What other information should I know about using ADSTILADRIN?

For two days following treatment, voided urine should be disinfected for 15 minutes with an equal volume of bleach before flushing.

For more important information, call 1-888-337-7464.

Please see full Prescribing Information.